Valbenazine in Obsessive Compulsive Disorder

Starting soon · Phase 2 · Has a placebo group

Conditions studied: Obsessive-Compulsive Disorder

In brief

The primary aim of the study is to examine the efficacy and safety of valbenazine in adults with moderate to severe obsessive-compulsive disorder (OCD).

Key facts

Study ID: NCT07111988
Run by: University of Chicago
People needed: 30
Starts: 2026-06-01
Expected to finish: 2027-12-01
Last updated by the study team: 2026-06-10

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Men and women aged 18-65 years
Primary diagnosis of obsessive compulsive disorder (OCD)
Yale Brown Obsessive Compulsive Scale (Y-BOCS) score of at least 21 at baseline (moderate or higher severity)
Ability to understand and sign the consent form

You may not qualify if…

Unstable medical illness based on history or clinically significant abnormalities on baseline physical examination
Current pregnancy or lactation, or inadequate contraception in women of childbearing potential
Subjects considered an immediate suicide risk based on the Columbia Suicide Severity Rating Scale (C-SSRS) (www.cssrs.columbia.edu/docs)
History of psychosis or bipolar disorder based on DSM-5 criteria
Alcohol/substance use disorder and/or illegal substance use based on urine toxicology
Initiation of psychological interventions within 3 months of screening (those who are continuing with CBT will be included)
Use of any new psychotropic medication within 3 months of study entry (stable doses of psychotropics will be allowed)
Major cognitive impairment that interferes with the capacity to understand and self-administer medication or provide written informed consent
Abnormal liver function tests at baseline (greater than 2x the upper limit of normal)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.